Journal of Gastrointestinal Surgery

, 11:158

Lymph Node Dissection Impact on Staging and Survival of Extrahepatic Cholangiocarcinomas, Based on U.S. Population Data

Article

DOI: 10.1007/s11605-006-0018-6

Cite this article as:
Schwarz, R.E. & Smith, D.D. J Gastrointest Surg (2007) 11: 158. doi:10.1007/s11605-006-0018-6

Abstract

Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973–2004 database. Out of 20,068 CC patients, 1,518 individuals were selected based on M0 stage and at least one LN examined. Primary cancer sites included gallbladder (29%), extrahepatic bile ducts (26%), and intrapancreatic/ampullary bile ducts (45%); 42% of patients were LN-positive. The median number of LNs examined was four (range 1–39). Median survival was 37 months for LN-negative and 16 months for LN-positive cancers. Multivariate prognostic variables were the number of positive LNs, primary site, age (all at p < 0.0001), gender (p = 0.002), size (p = 0.005), T category (p = 0.009), and total LN count (or number of negative LNs obtained, p = 0.01). The impact of total LN counts was seen in LN-negative (median survival, 1 vs 10 or more LNs examined: 27 vs 51 months, p = 0.002) and LN-positive disease (10 vs 22 months, p < 0.0001). Survival prediction of extrahepatic CCs is strongly influenced by total LN counts and numbers of negative LNs obtained. Although the resulting incremental benefit is small, dissection and examination of 10 or more LNs should be considered for curative intent resections.

Keywords

Extrahepatic cholangiocarcinomaLymph node countGallbladder cancerAmpullary cancerLymphadenectomySurvival

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Division of Surgical OncologyThe Cancer Institute of New JerseyNew BrunswickUSA
  2. 2.Division of BiostatisticsCity of Hope Cancer CenterDuarteUSA
  3. 3.Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical SchoolThe Cancer Institute of New JerseyNew BrunswickUSA